These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 21047493

  • 1. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
    Dretzke J, Round J, Connock M, Tubeuf S, Pennant M, Fry-Smith A, Hulme C, McCabe C, Meads C.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
    [Abstract] [Full Text] [Related]

  • 2. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M, Taylor DC, Parthan A, Coombs J, Paolantonio M, Sasane M.
    J Med Econ; 2013 Sep; 16(1):150-9. PubMed ID: 22762291
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 5. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S, Pilgrim H, Hind D.
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
    Bond M, Hoyle M, Moxham T, Napier M, Anderson R.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():69-74. PubMed ID: 19804692
    [Abstract] [Full Text] [Related]

  • 8. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C, Pitt M, Moxham T, Stein K.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G.
    Clin Drug Investig; 2007 Oct; 27(2):85-93. PubMed ID: 17217313
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D.
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [Abstract] [Full Text] [Related]

  • 11. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R.
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [Abstract] [Full Text] [Related]

  • 12. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 13. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
    Cohen MH, Cortazar P, Justice R, Pazdur R.
    Oncologist; 2010 Mar 28; 15(3):300-7. PubMed ID: 20200041
    [Abstract] [Full Text] [Related]

  • 14. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
    Dretzke J, Barton P, Kaambwa B, Connock M, Uthman O, Bayliss S, Meads C.
    Health Technol Assess; 2010 Oct 28; 14(Suppl. 2):19-26. PubMed ID: 21047487
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.
    J Surg Oncol; 2011 Dec 28; 104(7):760-4. PubMed ID: 21713778
    [Abstract] [Full Text] [Related]

  • 16. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.
    Health Technol Assess; 2010 Oct 28; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [Abstract] [Full Text] [Related]

  • 17. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J, Gospodarevskaya E, Frampton G, Cooper K.
    Health Technol Assess; 2009 Oct 28; 13 Suppl 3():31-6. PubMed ID: 19846026
    [Abstract] [Full Text] [Related]

  • 18. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
    Mabasa VH, Taylor SC, Chu CC, Moravan V, Johnston K, Peacock S, Knowling M.
    J Oncol Pharm Pract; 2008 Sep 28; 14(3):105-12. PubMed ID: 18524863
    [Abstract] [Full Text] [Related]

  • 19. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.
    Essat M, Cooper K.
    Int J Cancer; 2011 May 01; 128(9):2202-14. PubMed ID: 21387287
    [Abstract] [Full Text] [Related]

  • 20. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
    Li J, Gong JF, Wu AW, Shen L.
    Eur J Surg Oncol; 2011 Apr 01; 37(4):319-24. PubMed ID: 21277730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.